We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Verici Dx Plc (VRCI) ORD GBP0.001

Sell:2.25p Buy:2.50p 0 Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.25p
Buy:2.50p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.25p
Buy:2.50p
Change: No change
Market closed |  Prices as at close on 24 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Contact details

Address:
393 Nichol Mill Lane, Suite 200
FRANKLIN
37067
United States
Telephone:
+ (0)
Website:
https://vericidx.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 15 July 2024 15/07/24
AGM 25 June 2024 25/06/24
Annual report 31 May 2024 31/05/24
Final results 30 May 2024 30/05/24
General meeting 19 February 2024 19/02/24

General stock information

EPIC:
VRCI
ISIN:
GB00BM8HZD43
Market cap:
£5.76 million
Shares in issue:
242.54 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Sara Barrington
    Chief Executive Officer, Executive Director
  • David Anderson
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.